Summary
Three patients with lung cancer (1 SCLC, 2 NSCLC) and pericardial malignant effusion received 100 mg/m2 Teniposide (VM 26) i.v. and, 1 week later, 50 mg/m2 intrapericardially. Plasma, pericardial, and urine levels of the drug were measured in all patients after the two treatments by a HPLC assay. After intrapericardial administration, a high VM 26 concentration was found in the pericardial cavity and slow systemic drug absorption was observed. Since the drug AUC after intrapericardial administration was approximately 15–21 times that after i.v. administration, it could be that this treatment is more effective against neoplastic deposits localized in the pericardium. Even though this small series does not permit conclusions to be drawn on the efficacy of VM 26 given intrapericardially, the lack of local toxicity, minimal systemic toxicity, and the response observed in two out of three patients given intrapericardial VM 26 suggest that further investigation should be carried out on this method of VM 26 administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen LM, Tejada F, Okonmah AD, Nordqvist S (1982) Combination of chemotherapy: the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? Cancer Chemother Pharmacol 7:151
Bokkel Huinink WW, Dubelman R, Aartsen E, Franklin H, McVie JG (1985) Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol [Suppl 4] 12:43
Bork E, Hansen M, Dombernowsky P, Hansen SW, Pedersen AG, Hansen HH (1986) Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients. J Clin Oncol 4:524
Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr (1983) Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the i.v. route. Cancer Treat Rep 67:235
Colombo T, Broggini M, Vaghi M, Amato G, Erba E, D'Incalci M (1986) Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. Eur J Cancer Clin Oncol 22:173
Davis S, Sharma SM, Blumberg ED, Kim CS (1978) Intrapericardial tetracycline for the management of cardiac tamponade secondary to malignant pericardial effusion. N Engl J Med 299:1113
D'Incalci M, Erba E, Vaghi M, Morasca L (1982) In vitro cytoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma. Eur J Cancer Clin Oncol 18:377
D'Incalci M, Farina P, Sessa C, Mangioni C, Garattini S (1982) Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers. Cancer Treat Rep 66:231
D'Incalci M, Rossi C, Sessa C, Urso R, Zucchetti M, Farina P, Mangioni C (1985) Pharmacokinetics of teniposide in patients with ovarian cancer. Cancer Treat Rep 69:73
Donelli MG, D'Incalci M, Garattini S (1984) Pharmacokinetic studies of anticancer drugs in tumor-bearing animals. Cancer Treat Rep 68:381
Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, Rivera G (1982) Pharmacokinetics of teniposide (VM 26) and etoposide (VP 16-213) in children with cancer. Cancer Chemother Pharmacol 7:147
Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MA (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7:21
Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Int Med 97:845
Howell SB, Pfeifle CE, Olshen RA (1984) Intraperitoneal chemotherapy with melphalan. Ann Int Med 101:14
Jones JM, Olman EA, Egorin MJ, Aisner J (1985) A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide. Cancer Chemother Pharmacol 14:172
King ME, Pfeifle CE, Howell SB (1984) Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma. J Clin Oncol 2:662
Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE (1982) Phase 1 and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265
Pretorius RG, Hacker NF, Berek JS, Ford LC, Hoeschele JD, Butler TA, Lagasse LD (1983) Pharmacokinetics of ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep 67: 1085
Rossi C, Zucchetti M, Sessa C, Urso R, Mangioni C, D'Incalci M (1984) Pharmacokinetic, study of VM 26 given as a prolonged IV infusion to ovarian cancer patients. Cancer Chemother Pharmacol 13:211
Rubinson R, Bolooki H (1972) Intrapleural tetracycline for control of malignant pleural effusion: A preliminary report. South Med J 65:847
Shepherd FA, Ginsberg JS, Evans WK, Scott JG, Oleksiuk F (1985) Tetracycline sclerosis in the management of malignant pericardial effusion. J Clin Oncol 3:1678
Smith FE, Lane M, Hudgins PT (1974) Conservative management of malignant pericardial effusion. Cancer 33:47
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT, Myers CE (1980) Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40:567
Thurber DL, Edwards JE, Achor RW (1962) Secondary malignant tumors of the pericardium. Circulation 26:228
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Figoli, F., Zanette, M.L., Tirelli, U. et al. Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. Cancer Chemother. Pharmacol. 20, 239–242 (1987). https://doi.org/10.1007/BF00570493
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570493